Astria Therapeutics (ATXS), Wednesday announced has granted exclusive development and commercialization rights in Japan for its investigational therapy navenibart to Kaken Pharmaceutical.
Navenibart, a long-acting monoclonal antibody in Phase 3 trials, is designed for the preventative treatment of hereditary angioedema.
Under the agreement, Astria will receive an upfront payment of $16 million, with the potential for another $16 million in milestone payments, along with tiered royalties of up to 30 percent and partial cost reimbursement for Phase 3 development.
Kaken will support the ongoing ALPHA-ORBIT Phase 3 trial in Japan, manage regulatory submissions, and help prepare for commercialization. Astria expects the funding from this agreement to support its operations into 2028.
ATXS is currently trading at $6.99, down $0.03 or 0.43 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.